| Treatment (n = 11) | Active control (n = 9) | Excluded (n = 6) | ||||||
---|---|---|---|---|---|---|---|---|---|
M | SD | R | M | SD | R | M | SD | R | |
Age | 15.86 | 0.68 | 15–17 | 15.52 | 0.95 | 13.7–17.1 | 15.27 | 0.86 | 14.2–16.8 |
FSIQ | 59.73 | 16.19 | 40–86 | 50.50 | 7.45 | 40–60 | 52.50 | 12.37 | 40–72 |
VCI | 55.27 | 11.56 | 45–82 | 51.88 | 10.44 | 45–69 | 47.50 | 6.12 | 45–60 |
PRI | 69.45 | 22.41 | 45–111 | 53.62 | 6.32 | 45–66 | 62.83 | 17.29 | 45–89 |
CPT-3 – d’ | 62.82 | 10.54 | 44–75 | 69.44 | 4.48 | 61–74 | 67.33 | 2.160 | 64–70 |
Pre-WIAT WR | 59.09 | 16.78 | 40–85 | 48.44 | 10.67 | 40–65 |  |  |  |
Pre-WIAT RC | 51.45 | 10.80 | 40–70 | 44.56 | 7.07 | 40–59 |  |  |  |
Pre-WIAT FA | 62.55 | 21.78 | 40-106 | 43.56 | 7.88 | 40-64 | Â | Â | Â |
Pre-WIAT FS | 53.73 | 16.08 | 41–87 | 42.89 | 2.03 | 41–47 |  |  |  |